Actively Recruiting
Comparing Limited Versus Intense Post-Surgery Follow-Up to Study Anxiety and Outcomes in Patients With Stage II-III Soft Tissue Sarcoma
Led by M.D. Anderson Cancer Center · Updated on 2026-09-14
227
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of two different follow-up schedules on anxiety in patients with stage II-III soft tissue sarcoma of the trunk and extremities after surgery. The study aims to understand how the frequency of surveillance imaging and visits influences fear of cancer recurrence and other patient-reported outcomes. This phase II trial focuses on supportive care to improve the experience of cancer survivors. Participants are assigned to groups based on their risk level. Low-risk patients are randomly assigned to either intense follow-up every 3 months for 2 years with CT scans and primary site imaging or limited follow-up every 6 months for 2 years with either CT or chest x-ray plus primary site imaging. High-risk patients receive intense follow-up every 3 months for 2 years. These procedures include various imaging tests and questionnaires. During the study, participants will complete surveys about anxiety and fear of cancer recurrence for up to 2 years. Researchers will monitor outcomes such as survival, recurrence, distress, depression, costs, and clinic visits. The main measure is the change in fear of recurrence over the first 12 months. Safety and overall experience will be tracked throughout the follow-up period until the study ends in 2027.
CONDITIONS
Brief Title
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
Research Team
C
Christina L Roland, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here